ALNYLAM PHARMACEUTICALS, INC. Gain (Loss) on Extinguishment of Debt
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Gain (Loss) on Extinguishment of Debt of -$42.47 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was -$3.33M.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2025 was -$42.47M.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2022 was -$76.59M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$42.47M 10-K · filed 2026-02-12 | ||
| 2025-09-30 | -$39.15M 10-Q · filed 2025-10-30 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 10-K · filed 2026-02-12 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-K · filed 2026-02-12 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$76.59M derived: sum of 2 quarters · filed 2025-02-13 | -$76.59M 10-K · filed 2025-02-13 | |
| 2022-09-30 | -$76.59M 10-Q · filed 2023-11-02 | -$76.59M 10-Q · filed 2023-11-02 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $0.00 derived: sum of 2 quarters · filed 2024-02-15 | $0.00 10-K · filed 2024-02-15 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-10-27 | $0.00 10-Q · filed 2022-10-27 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |